ENDPOINTS

Corrected: Mineralys aims to raise $250M; Coherus' staffing changes

Plus, news about BioNTech, Roche, Boehringer Ingelheim, CervoMed, Genmab, Inozyme Pharma, Valo Therapeutics and Agomab: Mineralys Therapeutics’ $250M follow-on offering: Stellar Phase 3 data for the company’s blood pressure drug lorundrostat sent ...

Mar 12, 2025 - 20:39
 0
Corrected: Mineralys aims to raise $250M; Coherus' staffing changes
Plus, news about BioNTech, Roche, Boehringer Ingelheim, CervoMed, Genmab, Inozyme Pharma, Valo Therapeutics and Agomab: Mineralys Therapeutics’ $250M follow-on offering: Stellar Phase 3 data for the company’s blood pressure drug lorundrostat sent ...
Read More

Tags:

Previous Article

Rare mammoth tusk found on West Texas ranch

Next Article

Dinosaur footprints unknowingly displayed in a high school for 20 years

Related Posts

Updates from Washington; A trio of Big Pharma deals; What do recent share buybacks mean for M&A?; and more

Updates from Washington; A trio of Big Pharma deals; Wh...

Feb 15, 2025  0

Post-Hoc: Pharma CEOs' alternative reality with Trump

Post-Hoc: Pharma CEOs' alternative reality with Trump

Feb 24, 2025  0

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

AstraZeneca’s SERD hits primary endpoint in late-stage ...

Feb 26, 2025  0